Description

Bionomics Limited is an Australian biopharmaceutical company operating at the clinical stage, dedicated to the discovery and advancement of innovative therapeutic compounds. Its research efforts primarily target central nervous system disorders and various cancers, with operations spanning Australia and the United States. A key experimental medicine in its portfolio is BNC210. This compound, which functions as a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, has successfully concluded Phase 2 trials for addressing social anxiety disorder and post-traumatic stress disorder. The company is also developing BNC375, a small molecule therapeutic aimed at improving cognitive function in patients suffering from Alzheimer's disease. Another asset, BNC101, a monoclonal antibody engineered to target cancer stem cells, has concluded its Phase 1 clinical assessment. Moreover, Bionomics is advancing BNC105, a vascular disrupting agent. This agent is currently in Phase 2 clinical trials for the treatment of refractory colorectal cancer and in Phase 1 trials for individuals with relapsed/refractory chronic lymphocytic leukemia. Further bolstering its capabilities, Bionomics Limited maintains a licensing agreement with the pharmaceutical giant Merck & Co., Inc. Established in 1996, the company maintains its corporate headquarters in Eastwood, Australia.